{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:48:48Z","timestamp":1777884528466,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Objective: To report a case of heparin-induced hepatotoxicity in a patient without prior liver dysfunction who received prophylactic doses of unfractionated heparin (UFH). Case Summary: A 70-year-old man with no prior liver dysfunction was admitted to the hospital for presyncope, secondary to dehydration, and new-onset congestive heart failure. Prophylactic UFH was initiated for deep vein thrombosis prophylaxis. Within 2 days, he developed increases in aspartate aminotransferase and alanine aminotransferase. By day 4, aspartate aminotransferase and alanine aminotransferase were greater than 5 and 9 times the upper limit of normal, respectively. Alkaline phosphatase and bilirubin were markedly elevated as well. UFH was discontinued on day 4, and liver enzymes subsequently normalized. Discussion: Hepatotoxicity, defined as increases in transaminases greater than 3 times the upper limit of normal, is relatively rare\u2014estimated to occur in only 5% of those receiving therapy with UFH. Concurrent elevations in bilirubin have rarely been reported. Enzymes typically begin to rise after 4 to 5 days of UFH use and return to normal within 2 weeks of discontinuation. Previously published case reports of heparin-induced hepatotoxicity have occurred with therapeutic doses of either UFH or low-molecular-weight heparins. Conclusions: Heparin-induced hepatotoxicity may occur more rapidly than previously described, and even with the use of prophylactic doses of UFH. Given their widespread use, it is important for clinicians to consider heparins in their differential as a potential cause of hepatotoxicity especially in patients without underlying hepatic disease.<\/jats:p>","DOI":"10.1177\/8755122518803363","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T05:31:11Z","timestamp":1538112671000},"page":"36-40","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Hepatotoxicity With Elevated Bilirubin Secondary to Prophylactic Doses of Unfractionated Heparin: A Case Report and Review of Heparin-Induced Hepatotoxicity"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-6592","authenticated-orcid":false,"given":"Michael","family":"Bosco","sequence":"first","affiliation":[{"name":"James J. Peters VA Medical Center, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Kish","sequence":"additional","affiliation":[{"name":"Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"bibr1-8755122518803363","unstructured":"Center for Drug Evaluation and Research. Summary review. Heparin sodium. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/201370Orig1s000SumR.pdf. Published April 11, 2011. Accessed September 11, 2018."},{"key":"bibr2-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb05765.x"},{"key":"bibr3-8755122518803363","unstructured":"Heparin sodium injection [package insert]. Lake Zurich, IL: Fresenius Kabi; 2016."},{"key":"bibr4-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2369"},{"key":"bibr5-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1177\/1358836X9800300109"},{"key":"bibr6-8755122518803363","first-page":"339","volume-title":"Drug-Induced Disorders","volume":"5","author":"Stricker BHCH.","edition":"2"},{"key":"bibr7-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.40"},{"key":"bibr8-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.1.108.34436"},{"key":"bibr9-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.603100"},{"key":"bibr10-8755122518803363","unstructured":"Center for Drug Evaluation and Research. Guidance for industry: Drug-induced liver injury: premarketing clinical evaluation. https:\/\/www.fda.gov\/downloads\/Guidances\/UCM174090.pdf. Published July 2009. Accessed September 11, 2018."},{"key":"bibr11-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021844"},{"key":"bibr12-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5975.77"},{"key":"bibr13-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1978.tb08428.x"},{"key":"bibr14-8755122518803363","unstructured":"Fragmin [package insert]. New York, NY: Pfizer Inc; 2007."},{"key":"bibr15-8755122518803363","unstructured":"Lovenox [package insert]. Bridgewater, NJ: Sanofi-Aventis; 1993."},{"key":"bibr16-8755122518803363","unstructured":"Innohep [package insert]. Parsippany, NJ; Leo Pharma Inc; 2010."},{"key":"bibr17-8755122518803363","unstructured":"LiverTox. Drug record. Heparin. https:\/\/livertox.nih.gov\/Heparin.htm. Accessed September 11, 2018."},{"key":"bibr18-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010465"},{"key":"bibr19-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1984.tb04999.x"},{"key":"bibr20-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb03633.x"},{"key":"bibr21-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558513"},{"key":"bibr22-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1080\/22953337.1986.11719167"},{"key":"bibr23-8755122518803363","first-page":"137","volume":"31","author":"Guevara A","year":"1993","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"bibr24-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1038\/nri1594"},{"key":"bibr25-8755122518803363","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-5-646"},{"key":"bibr26-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1981.tb09831.x"},{"key":"bibr27-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr28-8755122518803363","unstructured":"LiverTox. Drug record. Aspirin. https:\/\/livertox.nlm.nih.gov\/Aspirin.htm. Accessed September 11, 2018."},{"key":"bibr29-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011427301"},{"key":"bibr30-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/272046"},{"key":"bibr31-8755122518803363","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080311"},{"key":"bibr32-8755122518803363","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-015-0018-0"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122518803363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/8755122518803363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/8755122518803363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:35Z","timestamp":1777602515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/8755122518803363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1177\/8755122518803363"],"URL":"https:\/\/doi.org\/10.1177\/8755122518803363","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]}}}